Metabolic medicine · Evidence update
Retatrutide.
Beyond the headline number.
Published phase 3 findings, knee-pain and function evidence, and the questions that remain about safety, lasting benefits and approval.
The short version
Retatrutide now has published phase 3 evidence, but remains investigational. As of November 16, 2026, FDA states that it is not a component of an approved drug and cannot be compounded under federal law. [1] Trial findings do not establish a longevity treatment or guarantee an individual result.
What is retatrutide?
Retatrutide activates three hormone receptors: GLP-1, GIP and glucagon. That mechanism helps explain the research interest. Clinical trials determine which benefits and risks have actually been demonstrated. [6]
What did TRIUMPH-1 find?
TRIUMPH-1 randomized 2,339 adults with obesity without diabetes. Published in The New England Journal of Medicine on September 29, 2026, it reported the following average weight changes at 80 weeks. [2]
| Assigned trial group | Average change |
|---|---|
| Retatrutide 4 mg | −17.6% |
| Retatrutide 9 mg | −23.7% |
| Retatrutide 12 mg | −25.0% |
| Placebo | −3.9% |
Gastrointestinal adverse events were the most common. These findings are not evidence of human lifespan extension. [2]
Why do some headlines say 28.3%?
The 28.3% figure uses the efficacy estimand, an analysis addressing outcomes under continued-treatment assumptions. It answers a different question from the treatment-regimen analysis that produced the 25.0% figure above. The estimates are not interchangeable, and neither is a personal prediction. [3]
What about people with diabetes?
TRIUMPH-2 studied 1,152 adults with overweight or obesity and type 2 diabetes. At 80 weeks, the treatment-regimen analysis found average weight changes of −11.9%, −16.8% and −18.8% in the 4 mg, 9 mg and 12 mg groups, respectively, versus −5.1% with placebo. [4]
Gastrointestinal events, low blood pressure and altered skin sensations were more frequent with retatrutide. This is a different population from TRIUMPH-1; the numbers should not be pooled into a single promise. [4]
How did it compare with Ozempic?
On October 28, 2026, Lilly announced topline TRANSCEND-T2D-2 results in adults with type 2 diabetes. At 80 weeks, it reported weight reductions of 19.5% and 20.9% with retatrutide 9 mg and 12 mg, respectively, versus 9.4% with Ozempic 2 mg. Adverse-event discontinuation rates were 4.8%, 7.9% and 2.7%, respectively. [6]
These are sponsor-reported efficacy-estimand weight results from an open-label trial; the announcement said a detailed peer-reviewed report was forthcoming. The comparator was Ozempic 2 mg. This does not establish superiority over obesity-dose Wegovy or tirzepatide. [6]
Does it improve knee pain and function?
A November 8 NEJM report describes two trials in adults without diabetes who had painful knee osteoarthritis and BMI at least 27. TRIUMPH-4 randomized 445 people for 68 weeks; TRIUMPH-1-OA studied 574 for 80 weeks. The results below are from TRIUMPH-4. [8]
On the WOMAC pain scale (0–10, higher means worse pain), average scores fell 3.96 points in the assigned 9 mg group and 3.74 with 12 mg, versus 2.12 with placebo. Placebo-adjusted reductions were 1.83 points (95% CI 1.30–2.37) and 1.61 (1.07–2.16). Patient-reported physical function also improved. Trial doses identify groups, not instructions for use. [8]
What does this pain analysis assume?
These figures use the paper’s hybrid-treatment analysis. It estimates what would have happened without specified events suggesting treatment failure, such as prohibited knee procedures or excessive pain-medication use, while retaining other events such as treatment discontinuation. It differs from the paper’s all-events intention-to-treat analysis and from conference efficacy estimates. [8] [9]
In the TRIUMPH-4 safety groups, serious adverse events occurred in 14/147 (9.5%), 16/148 (10.8%) and 3/149 (2.0%) participants receiving 9 mg, 12 mg and placebo, respectively. These events are not automatically attributable to treatment. Adverse events led 27/148 (18.2%) of the 12 mg group and 6/149 (4.0%) of placebo recipients to stop treatment. Two retatrutide recipients died; investigators assessed the deaths as unrelated. Gastrointestinal events were common. [8] [9]
These findings do not establish improved strength, bone health, fewer joint replacements or longer life. Retatrutide remains investigational. The trials were funded by Lilly. [1] [8]
Evidence limit: detailed tables were checked in the author-accepted manuscript. Its 9 mg adverse-event discontinuation count differs between the narrative and table, so that rate is omitted pending verification. The final supplement was not reviewed.
What does this mean for longevity medicine?
Annume’s interpretation: weight, metabolic risk, physical function and survival answer different questions. A strong result in one should not stand in for evidence in the others.
The important follow-up is whether benefits last, how well treatment is tolerated, what happens to muscle and function, and whether outcome trials show fewer serious events. Improved biomarkers do not establish fewer heart attacks, transplants or joint replacements. A trial in people with obesity also cannot establish benefit for healthy adults seeking longevity treatment.
When could it be approved?
Lilly has stated a planned first-quarter 2027 submission. A filing plan is not an approval date, approved indication or availability guarantee. [7]
Annume tracks research and regulatory decisions. It does not offer retatrutide or a reservation for future treatment. Products marketed online for human use under a research label should not be assumed equivalent to the trial medicine. [1]
A useful question to take away
“Does this result apply to people like me, and what do we know about benefits beyond weight loss?”
These are research findings, not individualized treatment or dosing advice. Discuss available options with a licensed clinician.
Make sense of the next finding.
Follow metabolic and longevity research with the study, its context and its limits in view.
Explore research updatesRead the sources
- FDA concerns about unapproved GLP-1 drugsFDA · Retatrutide’s unapproved status, compounding restrictions and products marketed for research.
- TRIUMPH-1: retatrutide in adults with obesityThe New England Journal of Medicine · September 29, 2026 · Peer-reviewed phase 3 trial. PubMed record.
- Lilly’s TRIUMPH-1 resultsSponsor announcement · Treatment-regimen and efficacy-estimand findings.
- TRIUMPH-2: retatrutide in type 2 diabetesThe Lancet · Peer-reviewed phase 3 trial. PubMed record.
- TRIUMPH-5: retatrutide versus tirzepatideClinicalTrials.gov · Separate head-to-head trial. An estimated completion date is not a result.
- TRANSCEND-T2D-2: comparison with Ozempic 2 mgLilly · October 28, 2026 · Sponsor topline announcement.
- Lilly’s phase 3 update and filing plansSponsor statement · Planned submission does not establish approval or availability.
- Retatrutide in adults with knee osteoarthritis pain and obesityThe New England Journal of Medicine · November 8, 2026 · Peer-reviewed TRIUMPH-4 and TRIUMPH-1-OA report. Journal article; detailed tables checked in the University of Leeds / White Rose accepted manuscript, not the final supplement.
- Lilly medical information: knee-osteoarthritis trialsSponsor medical-information summary · Corroborating analysis definitions and Table 7 safety data; not independent evidence.
November 16, 2026: added the November 8 knee-osteoarthritis report and rechecked FDA status. This is a catch-up update, not a new trial announcement today. Earlier weight-loss and comparison coverage was last substantively revised November 7. Peer-reviewed reports and sponsor announcements are labeled separately.
Prepared with AI assistance. No article-specific clinician review is credited. Read our editorial standards and correction policy.